Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat

Brain Research

Volumn 952, Issue 2, 2002, Pages 188-199

  Zorrilla, Eric P ^a   Valdez, Glenn R ^a   Nozulak, Joachim ^b   Koob, George F ^a   Markou, Athina ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Amphetamine; Anxiety; Corticotropin releasing factor; Locomotor activity; Stress

Indexed keywords

2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; 5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; ANTALARMIN; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXAMPHETAMINE; DMP 695; DMP 904; PYRROLOPYRIMIDINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; ILLUMINATION; MALE; MAZE TEST; MOTOR ACTIVITY; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; SEDATION; WITHDRAWAL REFLEX;

ANIMALS; ANXIETY; CORTICOTROPIN-RELEASING HORMONE; HUMANS; MALE; MAZE LEARNING; MOTOR ACTIVITY; PYRIMIDINES; PYRROLES; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 0037131064     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03189-X     Document Type: Article

References (98)

1. Andrews N., File S.E. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur. J. Pharmacol. 235:1993;109-112.
2. Anseloni V.Z., Brandao M.L. Ethopharmacological analysis of behaviour of rats using variations of the elevated plus-maze. Behav. Pharmacol. 8:1997;533-540.
3. Arborelius L., Skelton K.H., Thrivikraman K.V., Plotsky P.M., Schulz D.W., Owens M.J. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: behavioral, endocrine and neurochemical effects in the rat. J. Pharmacol. Exp. Ther. 294:2000;588-597.
4. Bakshi V.P., Kalin N.H. Corticotropin-releasing hormone and animal models of anxiety: gene- environment interactions. Biol. Psychiatry. 48:2000;1175-1198.
5. Bakshi V.P., Smith-Roe S., Newman S.M., Grigoriadis D.E., Kalin N.H. Reduction of stress-induced behavior by antagonism of corticotropin-releasing hormone 2 (CRH2) receptors in lateral septum or CRH1 receptors in amygdala. J. Neurosci. 22:2002;2926-2935.
6. Baldwin H.A., Rassnick S., Rivier J., Koob G.F., Britton K.T. CRF antagonist reverses the 'anxiogenic' response to ethanol withdrawal in the rat. Psychopharmacology. 103:1991;227-232.
7. Baram T.Z., Chalmers D.T., Chen C., Koutsoukos Y., De Souza E.B. The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, nonpeptide CRF receptor antagonist. Brain Res. 770:1997;89-95.
8. Behan D.P., De Souza E.B., Lowry P.J., Potter E., Sawchenko P., Vale W.W. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Front. Neuroendocrinol. 16:1995;362-382.
9. Bertoglio L.J., Carobrez A.P. Previous maze experience required to increase open arms avoidance in rats submitted to the elevated plus-maze model of anxiety. Behav. Brain Res. 108:2000;197-203.
10. Biro E., Sarnyai Z., Penke B., Szabo G., Telegdy G. Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate ester in rats. Neuroendocrinology. 57:1993;340-345.
11. Bornstein S.R., Webster E.L., Torpy D.J., Richman S.J., Mitsiades N., Igel M., Lewis D.B., Rice K.C., Joost H.G., Tsokos M., Chrousos G.P. Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology. 139:1998;1546-1555.
12. Briscoe R.J., Cabrera C.L., Baird T.J., Rice K.C., Woods J.H. Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats. Brain Res. 881:2000;204-207.
13. Britton K.T., Lee G., Vale W., Rivier J., Koob G.F. Corticotropin releasing factor (CRF) receptor antagonist blocks activating and 'anxiogenic' actions of CRF in the rat. Brain Res. 369:1986;303-306.
14. Chen C., Dagnino R. Jr., De Souza E.B., Grigoriadis D.E., Huang C.Q., Kim K.I., Liu Z., Moran T., Webb T.R., Whitten J.P., Xie Y.F., McCarthy J.R. Design and synthesis of a series of nonpeptide high-affinity human corticotropin-releasing factor1 receptor antagonists. J. Med. Chem. 39:1996;4358-4360.
15. Chen Y.L., Mansbach R.S., Winter S.M., Brooks E., Collins J., Corman M.L., Dunaiskis A.R., Faraci W.S., Gallaschun R.J., Schmidt A., Schulz D.W. Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist. J. Med. Chem. 40:1997;1749-1754.
16. Chorvat R.J., Bakthavatchalam R., Beck J.P., Gilligan P.J., Wilde R.G., Cocuzza A.J., Hobbs F.W., Cheeseman R.S., Curry M., Rescinito J.P., Krenitsky P., Chidester D., Yarem J.A., Klaczkiewicz J.D., Hodge C.N., Aldrich P.E., Wasserman Z.R., Fernandez C.H., Zaczek R., Fitzgerald L.W., Huang S.M., Shen H.L., Wong Y.N., Chien B.M., Quon C.Y., Arvanitis A. Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines. J. Med. Chem. 42:1999;833-848.
17. Cole B.J., Cador M., Stinus L., Rivier J., Vale W., Koob G.F., Le Moal M. Central administration of a CRF antagonist blocks the development of stress-induced behavioral sensitization. Brain Res. 512:1990;343-346.
18. Cole B.J., Koob G.F. Low doses of corticotropin-releasing factor potentiate amphetamine-induced stereotyped behavior. Psychopharmacology. 99:1989;27-33.
19. Contarino A., Dellu F., Koob G.F., Smith G.W., Lee K.F., Vale W., Gold L.H. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res. 835:1999;1-9.
20. Contarino A., Dellu F., Koob G.F., Smith G.W., Lee K.F., Vale W.W., Gold L.H. Dissociation of locomotor activation and suppression of food intake induced by CRF in CRFR1-deficient mice. Endocrinology. 141:2000;2698-2702.
21. Cruz A.P., Frei F., Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49:1994;171-176.
22. De Souza E.B. Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology. 20:1995;789-819.
23. Deak T., Nguyen K.T., Ehrlich A.L., Watkins L.R., Spencer R.L., Maier S.F., Licinio J., Wong M.L., Chrousos G.P., Webster E., Gold P.W. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology. 140:1999;79-86.
24. Dunn A.J., Berridge C.W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res. Rev. 15:1990;71-100.
25. Dunn A.J., Swiergiel A.H. Behavioral responses to stress are intact in CRF-deficient mice. Brain Res. 845:1999;14-20.
26. Fernandes C., File S.E. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol. Biochem. Behav. 54:1996;31-40.
27. Fernandes C., Gonzalez M.I., Wilson C.A., File S.E. Factor analysis shows that female rat behaviour is characterized primarily by activity, male rats are driven by sex and anxiety. Pharmacol. Biochem. Behav. 64:1999;731-738.
28. File S.E., Zangrossi H. Jr., Viana M., Graeff F.G. Trial 2 in the elevated plus-maze: a different form of fear? Psychopharmacology. 111:1993;491-494.
29. Gilligan P.J., Baldauf C., Cocuzza A., Chidester D., Zaczek R., Fitzgerald L.W., McElroy J., Smith M.A., Shen H.S., Saye J.A., Christ D., Trainor G., Robertson D.W., Hartig P. The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo- [1,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonist. Bioorg. Med. Chem. 8:2000;181-189.
30. Gilligan P.J., Robertson D.W., Zaczek R. Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. J. Med. Chem. 43:2000;1641-1660.
31. Goeders N.E., Guerin G.F. Effects of the CRH receptor antagonist CP-154,526 on intravenous cocaine self-administration in rats. Neuropsychopharmacology. 23:2000;577-586.
32. Griebel G., Perrault G., Sanger D.J. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology. 138:1998;55-66.
33. Griebel G., Simiand J., Steinberg R., Jung M., Gully D., Roger P., Geslin M., Scatton B., Maffrand J.P., Soubrie P. 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4- methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J. Pharmacol. Exp. Ther. 301:2002;333-345.
34. Habib K.E., Weld K.P., Rice K.C., Pushkas J., Champoux M., Listwak S., Webster E.L., Atkinson A.J., Schulkin J., Contoreggi C., Chrousos G.P., McCann S.M., Suomi S.J., Higley J.D., Gold P.W. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. 97:2000;6079-6084.
35. Harro J., Tonissaar M., Eller M. The effects of CRA 1000, a non-peptide antagonist of corticotropin-releasing factor receptor type 1, on adaptive behaviour in the rat. Neuropeptides. 35:2001;100-109.
36. He L., Gilligan P.J., Zaczek R., Fitzgerald L.W., McElroy J., Shen H.S., Saye J.A., Kalin N.H., Shelton S., Christ D., Trainor G., Hartig P. 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo [1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist. J. Med. Chem. 43:2000;449-456.
37. Heinrichs S.C., Joppa M. Dissociation of arousal-like from anxiogenic-like actions of brain corticotropin-releasing factor receptor ligands in rats. Behav. Brain Res. 122:2001;43-50.
38. Heinrichs S.C., Lapsansky J., Lovenberg T.W., De Souza E.B., Chalmers D.T. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regul. Pept. 71:1997;15-21.
39. Heinrichs S.C., Menzaghi F., Pich E.M., Baldwin H.A., Rassnick S., Britton K.T., Koob G.F. Anti-stress action of a corticotropin-releasing factor antagonist on behavioral reactivity to stressors of varying type and intensity. Neuropsychopharmacology. 11:1994;179-186.
40. Heinrichs S.C., Pich E.M., Miczek K.A., Britton K.T., Koob G.F. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res. 581:1992;190-197.
41. Hikichi T., Akiyoshi J., Yamamoto Y., Tsutsumi T., Isogawa K., Nagayama H. Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharmacopsychiatry. 33:2000;189-193.
42. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54:1996;21-30.
43. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 33:1999;181-214.
44. Hotta M., Shibasaki T., Arai K., Demura H. Corticotropin-releasing factor receptor type 1 mediates emotional stress-induced inhibition of food intake and behavioral changes in rats. Brain Res. 823:1999;221-225.
45. Hsin L.W., Tian X., Webster E.L., Coop A., Caldwell T.M., Jacobson A.E., Chrousos G.P., Gold P.W., Habib K.E., Ayala A., Eckelman W.C., Contoreggi C., Rice K.C. CRHR1 Receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists. Bioorg. Med. Chem. 10:2002;175-183.
46. Jasnow A.M., Banks M.C., Owens E.C., Huhman K.L. Differential effects of two corticotropin-releasing factor antagonists on conditioned defeat in male Syrian hamsters (Mesocricetus auratus). Brain Res. 846:1999;122-128.
47. Kask A., Rago L., Harro J. Alpha-helical CRF(9-41) prevents anxiogenic-like effect of NPY Y1 receptor antagonist BIBP3226 in rats. NeuroReport. 8:1997;3645-3647.
48. Keck M., Welt T., Wigger A., Renner U., Engelmann M., Holsboer F., Landgraf R. The anxiolytic effect of the CRH1 receptor antagonist R121919 depends on innate emotionality in rats. Eur. J. Neurosci. 13:2001;373-380.
49. Kehne J.H., Coverdale S., McCloskey T.C., Hoffman D.C., Cassella J.V. Effects of the CRF(1) receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in rat pups. Neuropharmacology. 39:2000;1357-1367.
50. Keller C., Bruelisauer A., Lemaire M., Enz A. Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. Drug Metab. Dispos. 30:2002;173-176.
51. Kikusui T., Takeuchi Y., Mori Y. Involvement of corticotropin-releasing factor in the retrieval process of fear-conditioned ultrasonic vocalization in rats. Physiol. Behav. 71:2000;323-328.
52. Koob G.F., Heinrichs S.C. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res. 848:1999;141-152.
53. Koob G.F., Heinrichs S.C., Pich E.M., Menzaghi F., Baldwin H., Miczek K., Britton K.T. The role of corticotropin-releasing factor in behavioural responses to stress. Ciba Found. Symp. 172:1993;277-289.
54. Koob G.F., Swerdlow N., Seeligson M., Eaves M., Sutton R., Rivier J., Vale W. Effects of α-flupenthixol and naloxone on CRF-induced locomotor activation. Neuroendocrinology. 39:1984;459-464.
55. Koob G.F., Thatcher-Britton K. Stimulant and anxiogenic effects of corticotropin releasing factor. Prog. Clin. Biol. Res. 192:1985;499-506.
56. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K., Donaldson C., Vaughan J., Reyes T.M., Gulyas J., Fischer W., Bilezikjian L., Rivier J., Sawchenko P.E., Vale W.W. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. 98:2001;7570-7575.
57. Liebsch G., Landgraf R., Engelmann M., Lorscher P., Holsboer F. Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J. Psychiatr. Res. 33:1999;153-163.
58. Liebsch G., Landgraf R., Gerstberger R., Probst J.C., Wotjak C.T., Engelmann M., Holsboer F., Montkowski A. Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul. Pept. 59:1995;229-239.
59. Lundkvist J., Chai Z., Teheranian R., Hasanvan H., Bartfai T., Jenck F., Widmer U., Moreau J.L. A nonpeptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur. J. Pharmacol. 309:1996;195-200.
60. Mansbach R.S., Brooks E.N., Chen Y.L. Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur. J. Pharmacol. 323:1997;21-26.
61. Martinez V., Tache V., Tache Y. Role of CRF receptor 1 in central CRF-induced stimulation of colonic propulsion in rats. Brain Res. 893:2001;29-35.
62. Menzaghi F., Heinrichs S.C., Merlo-Pich E., Tilders F.J., Koob G.F. Involvement of hypothalamic corticotropin-releasing factor neurons in behavioral responses to novelty in rats. Neurosci. Lett. 168:1994;139-142.
63. Menzaghi F., Howard R.L., Heinrichs S.C., Vale W., Rivier J., Koob G.F. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J. Pharmacol. Exp. Ther. 269:1994;564-572.
64. Millan M.J., Brocco M., Gobert A., Dorey G., Casara P., Dekeyne A. Anxiolytic properties of the selective, non-peptidergic corticotropin-releasing factor (CRF)1 antagonists, CP154,526 and DMP 695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology. 25:2001;585-600.
65. Moreau J.L., Kilpatrick G., Jenck F. Urocortin, a novel neuropeptide with anxiogenic-like properties. NeuroReport. 8:1997;1697-1701.
66. Nakazato A., Kumagai T., Okubo T., Tanaka H., Chaki S., Okuyama S., Tomisawa K. Design, synthesis and structure-affinity relationships of 4-methylidenepiperidine and 4-aryl-1,2,3,6-tetrahydropyridine derivatives as corticotropin-releasing factor1 receptor antagonists. Bioorg. Med. Chem. 8:2000;1183-1193.
67. Nijsen M.J., Croiset G., Stam R., Bruijnzeel A., Diamant M., de Wied D., Wiegant V.M. The role of the CRH type 1 receptor in autonomic responses to corticotropin-releasing hormone in the rat. Neuropsychopharmacology. 22:2000;388-399.
68. Ohata H., Suzuki K., Oki Y., Shibasaki T. Urocortin in the ventromedial hypothalamic nucleus acts as an inhibitor of feeding behavior in rats. Brain Res. 861:2000;1-7.
69. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S., Nakazato A., Kumagai T., Okubo T., Tomisawa K. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001. J. Pharmacol. Exp. Ther. 289:1999;926-935.
70. Owens M.J., Nemeroff C.B. Corticotropin-releasing factor antagonists in affective disorders. Exp. Opin. Invest. Drugs. 8:1999;1849-1858.
71. Pellegrino L.J., Pellegrino A.S., Cushman A.J. A Stereotaxic Atlas of the Rat Brain. 1979;Plenum, New York.
72. Pelleymounter M.A., Joppa M., Carmouche M., Cullen M.J., Brown B., Murphy B., Grigoriadis D.E., Ling N., Foster A.C. Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. J. Pharmacol. Exp. Ther. 293:2000;799-806.
73. Pellow S., File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 24:1986;525-529.
74. Penalva R.G., Flachskamm C., Zimmermann S., Wurst W., Holsboer F., Reul J.M., Linthorst A.C. Corticotropin-releasing hormone receptor type 1-deficiency enhances hippocampal serotonergic neurotransmission: an in vivo microdialysis study in mutant mice. Neuroscience. 109:2002;253-266.
75. Perrin M.H., Vale W.W. Corticotropin releasing factor receptors and their ligand family. Ann. NY Acad. Sci. 885:1999;312-328.
76. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A., Hogenesch J.B., Gulyas J., Rivier J., Vale W.W., Sawchenko P.E. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. 98:2001;2843-2848.
77. Schulz D.W., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M., Dunaiskis A., Faraci S., Schmidt A.W., Seeger T., Seymour P., Tingley F.D. III, Winston E.N., Chen Y.L., Heym J. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. 93:1996;10477-10482.
78. Shaham Y., Erb S., Leung S., Buczek Y., Stewart J. CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology. 137:1998;184-190.
79. Shrout P.E., Fleiss J.L. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 86:1979;420-428.
80. Sirinathsinghji D.J., Rees L.H., Rivier J., Vale W. Corticotropin-releasing factor is a potent inhibitor of sexual receptivity in the female rat. Nature. 305:1983;232-235.
81. Skutella T., Probst J.C., Renner U., Holsboer F., Behl C. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience. 85:1998;795-805.
82. Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., Chen R., Marchuk Y., Hauser C., Bentley C.A., Sawchenko P.E., Koob G.F., Vale W., Lee K.F. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 20:1998;1093-1102.
83. Spina M., Merlo-Pich E., Chan R.K., Basso A.M., Rivier J., Vale W., Koob G.F. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science. 273:1996;1561-1564.
84. Spina M.G., Basso A.M., Zorrilla E.P., Heyser C.J., Rivier J., Vale W., Merlo-Pich E., Koob G.F. Behavioral effects of central administration of the novel CRF antagonist astressin in rats. Neuropsychopharmacology. 22:2000;230-239.
85. Stenzel-Poore M.P., Heinrichs S.C., Rivest S., Koob G.F., Vale W.W. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J. Neurosci. 14:1994;2579-2584.
86. Swerdlow N.R., Koob G.F. Separate neural substrates of the locomotor-activating properties of amphetamine, heroin, caffeine and corticotropin releasing factor (CRF) in the rat. Pharmacol. Biochem. Behav. 23:1985;303-307.
87. Swerdlow N.R., Vaccarino F.J., Amalric M., Koob G.F. The neural substrates for the motor-activating properties of psychostimulants: a review of recent findings. Pharmacol. Biochem. Behav. 25:1986;233-248.
88. Takahashi L.K., Kalin N.H., Vanden Burgt J.A., Sherman J.E. Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav. Neurosci. 103:1989;648-654.
89. Tazi A., Swerdlow N.R., LeMoal M., Rivier J., Vale W., Koob G.F. Behavioral activation by CRF: evidence for the involvement of the ventral forebrain. Life Sci. 41:1987;41-49.
90. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., Blanquet V., Steckler T., Holsboer F., Wurst W. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor. Nat. Genet. 19:1998;162-166.
91. Trullas R., Winslow T.R., Insel T.R., Skolnick P. Are glutamatergic pathways involved in the pathophysiology of anxiety. Briley M., File S.E., New Concepts in Anxiety. 1991;382-394 CRC Press, Boca Raton.
92. Valdez G.R., Inoue K., Koob G.F., Rivier J., Vale W., Zorrilla E.P. Human urocortin II: Mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res. 943:2002;142-150.
93. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science. 213:1981;1394-1397.
94. Wall P.M., Messier C. Ethological confirmatory factor analysis of anxiety-like behaviour in the murine elevated plus-maze. Behav. Brain Res. 114:2000;199-212.
95. Webster E.L., Lewis D.B., Torpy D.J., Zachman E.K., Rice K.C., Chrousos G.P. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology. 137:1996;5747-5750.
96. Yang X.M., Gorman A.L., Dunn A.J. The involvement of central noradrenergic systems and corticotropin-releasing factor in defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 255:1990;1064-1070.
97. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34:2000;171-181.
98. Zorrilla E.P., Koob G.F. Urocortin. Fink G., Encyclopedia of Stress. Vol. 3:2000;637-641 Academic Press, San Diego.